My cardiologist just high-fived me at my checkup lol

Adding the clinical framing, because it changes how the question reads.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

• NT-proBNP: 65 pg/mL (normal, cardiac function preserved)
• Lp(a): 45 nmol/L (genetic, unchanged — expected)
• ApoB: dropped from 145 to 90 mg/dL (excellent response)
• Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

Dr.AddMedPHL said:

I want to bring up the cardiovascular angle on cardiovascular risk.

Senior perspective on cardiovascular risk: I'm 65 years old and started this journey skeptically. My endocrinologist recommended it after years of failed interventions.

15 months later: down 53 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Dr.AddMedPHL said:

I want to bring up the cardiovascular angle on cardiovascular risk.

Thank you for spelling out the reasoning rather than just the conclusion.

From the other side of the consultation, briefly.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

Moderator note: a couple of off-topic posts removed.